Loading...
XIDX
DVLA
Market cap111mUSD
Nov 12, Last price  
1,655.00IDR
Name

Darya-Varia Laboratoria Tbk PT

Chart & Performance

D1W1MN
XIDX:DVLA chart
P/E
11.87
P/S
0.89
EPS
139.42
Div Yield, %
3.93%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
2.86%
Revenues
2.09t
+10.40%
869,170,910,000929,196,665,000972,297,437,0001,087,379,869,0001,101,684,170,0001,103,821,775,0001,306,098,136,0001,451,356,680,0001,575,647,308,0001,699,657,296,0001,813,020,278,0001,829,699,557,0001,900,893,602,0001,917,041,442,0001,890,887,506,0002,087,601,399,000
Net income
156.15b
+6.70%
72,272,233,000110,880,522,000120,915,340,000148,909,089,000125,796,473,00080,929,476,000107,894,430,000152,083,400,000162,249,293,000200,651,968,000221,783,249,000162,072,984,000146,505,337,000149,375,011,000146,336,365,000156,147,303,000
CFO
331.76b
+203.85%
5,688,757,000130,614,145,00072,518,015,000119,207,439,000106,931,180,000104,436,317,000214,166,823,000187,475,539,000230,738,193,00026,628,428,000272,538,844,000106,583,179,000435,333,430,000182,497,211,000109,185,785,000331,762,800,000
Dividend
Jun 24, 202465 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas. The company also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.
URL
https://www.darya-varia.com/
IPO date
Nov 11, 1994
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT